MIRA
INFORM REPORT
|
Report Date : |
17.10.2007 |
IDENTIFICATION DETAILS
|
Name : |
Shiminab Chemical & Pharmaceutical Company |
|
|
|
|
Registered Office : |
Unit.7, 2nd Floor, No. 947, Kasra Bldg, Shariati Ave, Tehran
1953613413 |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
1994 |
|
|
|
|
Com. Reg. No.: |
123132 |
|
|
|
|
Legal Form : |
Private Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacture and Supplier of scientific, genomics, and
Pharmaceutical Products. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Company Details
Company Name: Shiminab
Chemical & Pharmaceutical Company
Address: Unit.7,
2nd Floor,No.947, Kasra Bldg,
Telephone: +98 221 2262328
+98 21 66497256
Fax: +98 21 66497256
Website: www.shimi-nab.com
E-mail : info@shimi-nab.com
Registration &
Legal Details
Current Legal Form: PRIVATE JOINT STOCK CO
Registration
Address: Unit.7, 2nd Floor,No.947, Kasra Bldg,
Registration Number: 123132
Established Date: 1994
Registration Date: 1994
History
Company was originally started as a privet
Joint Stock on 1994
Capital
Nominal capital: 5,000,000,000
Iranian Rial
Issued capital: 5,000,000,000
Iranian Rial
Paid up capital: All
Number of Shares: 1,000 Type of Shares: None Selected
Issued Shares: Value per share: IRI 5,000,000.00
Shareholders
Information on
shareholder is not available.
Principals
Name: Mr. Ali Movahednia
Position within the company: Managing director
Country of Birth:
Nationality: Iranian
Can fluently speak: English-Farsi
Name: Mr. Morteza Ghafour
Position within the company: Member
Country of Birth:
Nationality: Iranian
Can fluently speak: Farsi-English
Name: Mr. Amir Torabi
Position within the company: Director
Country of Birth:
Nationality: Iranian
Can fluently speak: Farsi-English
Name: Ms. Kiana Moein
Position within the company: Secretary
Country of Birth:
Nationality: Iranian
Can fluently speak: Farsi-English
Company Activities
Manufacture and Supplier
of scientific, genomics, and Pharmaceutical Products.
Local Reporters consider the investigated company to be Medium
in their field of concern.
Company Employs
65
Sales
%100 Nationality
Sales to
Local Authorities, Group
Companies
Sales Term
Cash, Check
Vehicles
15
HQ Premises
Operates Form: Owned:
Office, Warehouse, and Factory
Location: Central Business Area, Side Road
Branch: Shiminab Store
No. 133, Rajabbeygi
( Malek ) Alley ,
Bankers
Bank Mellat
Bank Melli
Ferdosi Branch
No.73,
Fax: +98 21 88809919
Financial
information
Source: Ms. Kiana Moein(Secretary)
Currency: Iranian Rails
Note: Figures in 000,000's
Months Sales
Figures Sales Gross Profit/Loss Net Profit/Loss
12 29/03/2006 17,700.00
12 29/03/2005 14,500.00
12 29/03/2004 13,200.00
Imports
Imports From: Europe,
Importing Terms:
Letters of credit
Import % and type of product: %15
Raw Material %10 Finished Good
Additional Information: Balance of %75 purchased via local market.
Export
Subject dose not have any
Export.
Related Companies
Subject doesn't have any
Related company
Payment
Subject's payments reported to be: NO COMPLAINTS
Interview & Reporter Comments
In the interview
conducted with Ms. Kiana Moein (Secretary), she declined financial information
and bank account number citing the grounds of company confidentiality.
Name/Title: Ms. Kiana
Moein (Secretary)
Subject has confirmed the details provided in the report.
Conclusions
Local Reputation:
The company being investigated is believed by local reporters to be a High Trade
Risk.
Owner/Shareholders Comments
All or most of the owners / shareholders have an active participation in the running of
the business.
Age of Business:
Old Business
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)